263 related articles for article (PubMed ID: 17143501)
21. Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients.
Lanchou J; Corbel M; Tanguy M; Germain N; Boichot E; Theret N; Clement B; Lagente V; Malledant Y
Crit Care Med; 2003 Feb; 31(2):536-42. PubMed ID: 12576963
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer.
Passlick B; Sienel W; Seen-Hibler R; Wöckel W; Thetter O; Mutschler W; Pantel K
Clin Cancer Res; 2000 Oct; 6(10):3944-8. PubMed ID: 11051242
[TBL] [Abstract][Full Text] [Related]
23. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
[TBL] [Abstract][Full Text] [Related]
24. Time course of matrix metalloproteases and tissue inhibitors in bleomycin-induced pulmonary fibrosis.
Oggionni T; Morbini P; Inghilleri S; Palladini G; Tozzi R; Vitulo P; Fenoglio C; Perlini S; Pozzi E
Eur J Histochem; 2006; 50(4):317-25. PubMed ID: 17213041
[TBL] [Abstract][Full Text] [Related]
25. Increased matrix metalloproteinases 2 and 9 and tissue inhibitor of matrix metalloproteinase 2 expression is associated with progression from vulvar intraepithelial neoplasia to invasive carcinoma.
Määttä M; Santala M; Soini Y; Turpeenniemi-Hujanen T; Talvensaari-Mattila A
Acta Obstet Gynecol Scand; 2010 Mar; 89(3):380-4. PubMed ID: 20109015
[TBL] [Abstract][Full Text] [Related]
26. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, beta-catenin and prognosis.
Leinonen T; Pirinen R; Böhm J; Johansson R; Ropponen K; Kosma VM
Lung Cancer; 2006 Mar; 51(3):313-21. PubMed ID: 16423426
[TBL] [Abstract][Full Text] [Related]
27. Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer.
Cai M; Onoda K; Takao M; Kyoko IY; Shimpo H; Yoshida T; Yada I
Clin Cancer Res; 2002 Apr; 8(4):1152-6. PubMed ID: 11948127
[TBL] [Abstract][Full Text] [Related]
28. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue.
Brehmer B; Biesterfeld S; Jakse G
Prostate Cancer Prostatic Dis; 2003; 6(3):217-22. PubMed ID: 12970724
[TBL] [Abstract][Full Text] [Related]
29. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension.
Palei AC; Sandrim VC; Cavalli RC; Tanus-Santos JE
Clin Biochem; 2008 Jul; 41(10-11):875-80. PubMed ID: 18477480
[TBL] [Abstract][Full Text] [Related]
30. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy.
Pritchard SC; Nicolson MC; Lloret C; McKay JA; Ross VG; Kerr KM; Murray GI; McLeod HL
Oncol Rep; 2001; 8(2):421-4. PubMed ID: 11182067
[TBL] [Abstract][Full Text] [Related]
31. Expression and clinical significance of matrix metalloproteinase (MMP)-26 protein in non-small cell lung cancer.
Li L; Mei TH; Zhou XD; Zhang XG
Ai Zheng; 2009 Jan; 28(1):60-3. PubMed ID: 19448419
[TBL] [Abstract][Full Text] [Related]
32. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer.
Shou Y; Hirano T; Gong Y; Kato Y; Yoshida K; Ohira T; Ikeda N; Konaka C; Ebihara Y; Zhao F; Kato H
Br J Cancer; 2001 Nov; 85(11):1706-12. PubMed ID: 11742492
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.
Pennanen H; Kuittinen O; Soini Y; Turpeenniemi-Hujanen T
Eur J Haematol; 2008 Oct; 81(4):289-97. PubMed ID: 18616513
[TBL] [Abstract][Full Text] [Related]
34. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
[TBL] [Abstract][Full Text] [Related]
35. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer.
Byun JH; Lee MA; Roh SY; Shim BY; Hong SH; Ko YH; Ko SJ; Woo IS; Kang JH; Hong YS; Lee KS; Lee AW; Park GS; Lee KY
Jpn J Clin Oncol; 2006 May; 36(5):263-8. PubMed ID: 16735371
[TBL] [Abstract][Full Text] [Related]
36. [Expression and significance of matrix metalloproteinase and tissue inhibitor of metalloproteinase in nasal cavity squamous cell carcinoma].
Zheng Y; Ding J; Wang CL; Jiao SS; Qu LM; Bahargul ; Bao H; Chen X
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Apr; 46(4):299-302. PubMed ID: 21624249
[TBL] [Abstract][Full Text] [Related]
37. Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma.
Yoshino Y; Kageshita T; Nakajima M; Funakubo M; Ihn H
J Dermatol; 2008 Apr; 35(4):206-14. PubMed ID: 18419677
[TBL] [Abstract][Full Text] [Related]
38. The balance between MMP-2/-9 and TIMP-1/-2 is shifted towards MMP in renal cell carcinomas and can be further disturbed by hydrogen peroxide.
Hemmerlein B; Johanns U; Halbfass J; Böttcher T; Heuser M; Radzun HJ; Thelen P
Int J Oncol; 2004 May; 24(5):1069-76. PubMed ID: 15067327
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer.
Shao W; Wang W; Xiong XG; Cao C; Yan TD; Chen G; Chen H; Yin W; Liu J; Gu Y; Mo M; He J
J Surg Oncol; 2011 Dec; 104(7):841-6. PubMed ID: 21721010
[TBL] [Abstract][Full Text] [Related]
40. Video-assisted thoracic surgery lobectomy for lung cancer is associated with less immunochemokine disturbances than thoracotomy.
Ng CS; Wan S; Hui CW; Wan IY; Lee TW; Underwood MJ; Yim AP
Eur J Cardiothorac Surg; 2007 Jan; 31(1):83-7. PubMed ID: 17118669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
